Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2

4(50.0%)

Phase 1

4(50.0%)

8Total

Phase 2(4)

Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07521852Phase 2Recruiting

A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC

Role: lead

NCT05257590Phase 2Recruiting

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

Role: lead

NCT06143774Phase 1Recruiting

Study of TRX-920 for Patients With Advanced Solid Tumors

Role: lead

NCT03600233Phase 2Active Not Recruiting

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

Role: lead

NCT03582618Phase 2Terminated

CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma

Role: lead

NCT04336124Phase 1Completed

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

Role: lead

NCT02507544Phase 1Completed

A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer

Role: lead

NCT02703298Phase 1Completed

Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients

Role: lead

All 8 trials loaded